Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-07-13
2000-03-07
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 42419511, 4241851, 4241921, 4241931, 4241941, 5303917, A61K 39385, A61K 3825
Patent
active
060340533
ABSTRACT:
A protein conjugate containing EGF coupled to a tyrosine kinase inhibitor such as Genistein, for inhibiting or preventing restenosis following vascular injury.
REFERENCES:
patent: 5587459 (1996-12-01), Uckun
patent: 5911995 (1999-06-01), Uckun
Aikyama, T., et al., 1987, J. Biol. Chem. 262, 5592-5595 "Genistein, a Specific Inhibitor of Tyrosine-Specific Protein Kinases".
Banks, J. G., et al., 1985, J. Appl. Bacteriol. 58, 391-400 "The Cytotoxic and Photodynamic Inactivation of Microorganisms by Rose Bengal".
Broome, M. A. et al., 1996, J. Biol. Chem. 271, 16798-16806 "Requirement for c-Src Catalytic Activity and the SH3 Domain in Platelet--Derived Growth Factor BB and Epidermal Growth Factor Mitogenic Signaling".
Earp, H. S., et al., 1995, Breast Cancer Research & Treatment 35, 115-132 "Heterodimerization and Functional Interaction Between EGF Receptor Family Members: a New Signaling Paradigm with Implications for Breast Cancer Research".
Fox, S.B., 1994, Breast Cancer Research & Treatment 29, 41-49 "The Epidermal Growth Factor Receptor as a Prognostic Marker; Results of 370 Patients and Review of 3009 Patients".
Landzberg, B.R., et al., 1997, Prog. Cardiovascular Diseases 39, 361-298 "Pathophysiology and Pharmacological Approaches for Prevention of Coronary Artery Restenosis Following Coronary Artery Balloon Angioplasty and Related Procedures".
Mullins, D.E., et al., 1994, Arterioscler. Thromb. 14, 1047-1055 "Inhibition of PDGF Receptor Binding and PDGF--Stimulated Biological Activity in vitro and of Intimal Lesion Formation in vivo by 2--Bromomethyl--5--Chlorobenzene Sulfonylphthalimide".
Muthuswamy, S.K., 1994, Molecular & Cellular Biology 14, 735-743 "Mammary Tumors Expressing the Neu Proto--Oncogene Possess Elevated c.sup.Src Tyrosine Kinase Activity".
Ottenhoff-Kalff, A.K., et al., 1992, Cancer Research 52, 4773-4778 "Characterization of Protein Tyrosine Kinases from Human Breast Cancer: Involvement of the c.sup.Src Oncogen Product".
Saltis, J., et al., 1995, Atherosclerosis 118, 77-87 "Expression of Growth Factor Receptors in Arterial Smooth Muscle Cells. Dependency on Cell Phenotype and Serum Factors".
Uckun, F.M., et al., 1995, Science 267, 886-891 "Biotherapy of B-13 cell Precursor Leukemia by Targeting Genistein to CD19-Associated Tyrosine Kinases".
Uckun, F.M., et al., 1998, Clinical Cancer Research, 4:901-912 "Cytotoxic Activity of EGF--Genistein Against Human Breast Cancer Cells".
Uckun, F.M., et al., 1998, Clinical Cancer Research 5:1125-1134 "In Vivo Toxicity Pharmacokinetics and Anti-Cancer Activity of Genistein Linked to Recombinant Human Epidermal Growth Factor".
Ueda, M., et al., 1995, Coron. Artery Dis. 6,71-81 "Smooth Muscle Cell De-differentiation is a Fundamental ChangePreceding Wound Healing After Percutaneous Transluminal Coronary Angioplasty in Humans".
Vaitkus, P.T., 1995, Coron. Artery Dis. 6, 429-439 "The Continuing Evolution of Percutaneous Transluminal Coronary Angioplasty in the Treatment of Coronary Artery Disease".
Wright, J.D., et al., 1995, J. Biol. Chem. 270, 12085-12093 "An Incomplete Program of Cellular Tyrosine Kinase Phosphorylation by Kinase--Defective Epidermal Growth Factor Receptors".
Ahmad, N. et al., "Skin Cancer Chemopreventive Effects of Flavonoid Antioxidant Silymarin Are Mediated via Impairment of Receptor Tyrosine Kinase Signaling and Perturbation in Cell Cycle Progression," Biochemical and Biophysical Research Communications, vol. 248, No. 2, pp. 294-301 (1998).
Baguley, B.C. et al., "Inhibition of Growth of Primary Human Tumor Cell Cultures by a 4--Anilinoquinazoline Inhibitor of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases," European Journal of Cancer, vol. 34, No. 7, pp. 1086-1090 (1998).
Levitzki, A. et al., "Tyrosine Kinase Inhibition: An Approach to Drug Development," Science, vol. 267, pp. 1782-1788 (Mar. 24, 1995).
Mattar, T. et al., "Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide," Febs. Letters, vol. 334, No. 2, pp. 161-164 (Nov. 1993).
Srivastava, A.K., "Inhibition of Phosphorylase Kinase, and Tyrosine Protein Kinase Activities by Quercetin," Biochemical and Biophysical Research Communications, vol. 131, No. 1, pp. 1-5 (Aug. 30, 1985).
Wakeling, A.E. et al., "Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4--anilinoquinazolines," Breast Cancer Research and Treatment, vol. 38, pp. 67-73 (1996).
Xu, X. et al., "Two Activities of the Immunosuppressive Metabolite of Leflunomide, A77 1726," Biochemical Pharmacology, vol. 52, pp. 527-534 (1996).
Trieu Vuong N.
Uckun Fatih M.
Moezie F. T.
Wayne Hughes Institute
LandOfFree
EGF-isoflavone conjugates for the prevention of restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EGF-isoflavone conjugates for the prevention of restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EGF-isoflavone conjugates for the prevention of restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-363071